{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:14:13Z","timestamp":1792084453579,"version":"4.4.0"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006772","name":"Max and Minnie Tomerlin Voelcker Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006772","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mindful Foundation"},{"name":"UTSA RISE-PhD program","award":["NIGMS RISE GM60655"],"award-info":[{"award-number":["NIGMS RISE GM60655"]}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>Mucormycosis (previously called zygomycosis) is a serious but rare fungal infection caused by a group of fungi belonging to the order Mucorales. These molds exist throughout the environment and generally do not cause serious problems in humans. Mucormycosis mainly affects individuals who are immunocompromised. The clinical manifestations of mucormycosis are wide-ranging; they include sinusitis (pansinusitis, rhino-orbital, or rhino-cerebral) as well as cutaneous, gastrointestinal, pulmonary, and disseminate infections. Many uncertainties remain regarding how to control these infections despite the recent addition of triazoles to the antifungal arsenal for treating this infection. Currently, lipid formulations of amphotericin B have become the standard treatment for mucormycosis due to their efficiency. Moreover, a growing body of data supports the need for surgical excision of infected and\/or necrosed tissue whenever practical. In this mini review, the current status of treatment options for mucormycosis and recent studies of novel therapeutic options will be presented.<\/jats:p>","DOI":"10.1371\/journal.ppat.1010858","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T17:25:21Z","timestamp":1665681921000},"page":"e1010858","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":67,"title":["Current treatments against mucormycosis and future directions"],"prefix":"10.1371","volume":"18","author":[{"given":"Courtney","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7792-5947","authenticated-orcid":true,"given":"Soo Chan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"issue":"2","key":"ppat.1010858.ref001","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1128\/CMR.00056-10","article-title":"Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species","volume":"24","author":"MZ Gomes","year":"2011","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"ppat.1010858.ref002","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1086\/422729","article-title":"Zygomycosis: Reemergence of an Old Pathogen","volume":"39","author":"CA Kauffman","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"9","key":"ppat.1010858.ref003","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.3201\/eid2709.210934","article-title":"Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India","volume":"27","author":"A Patel","year":"2021","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"ppat.1010858.ref004","article-title":"Connecting the Dots: Interplay of Pathogenic Mechanisms between COVID-19 Disease and Mucormycosis","volume":"7","author":"H Prakash","year":"2021","journal-title":"J Fungi (Basel)."},{"issue":"7","key":"ppat.1010858.ref005","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1016\/S2666-5247(21)00237-8","article-title":"The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries","volume":"3","author":"M Hoenigl","year":"2022","journal-title":"Lancet Microbe"},{"issue":"suppl_1","key":"ppat.1010858.ref006","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/cid\/cir880","article-title":"A Global Analysis of Mucormycosis in France: The RetroZygo Study (2005\u20132007)","volume":"54","author":"F Lanternier","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"ppat.1010858.ref007","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1093\/cid\/cir868","article-title":"Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis).","volume":"54","author":"TJ Walsh","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"3","key":"ppat.1010858.ref008","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/jof4030090","article-title":"Therapy of Mucormycosis.","volume":"4","author":"NV Sipsas","year":"2018","journal-title":"J Fungi (Basel)."},{"issue":"3","key":"ppat.1010858.ref009","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1128\/AAC.04435-14","article-title":"Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales","volume":"59","author":"A Espinel-Ingroff","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"ppat.1010858.ref010","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"OA Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"ppat.1010858.ref011","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/jac\/dkv236","article-title":"Prospective pilot study of high-dose (10 mg\/kg\/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis","volume":"70","author":"F Lanternier","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"ppat.1010858.ref012","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/myc.13335","article-title":"ECMM\/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries","volume":"64","author":"SM Rudramurthy","year":"2021","journal-title":"Mycoses"},{"issue":"7","key":"ppat.1010858.ref013","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"FM Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"ppat.1010858.ref014","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1086\/523576","article-title":"Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent","volume":"45","author":"V Nagappan","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"1","key":"ppat.1010858.ref015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/dkg020","article-title":"In vitro susceptibilities of zygomycetes to conventional and new antifungals","volume":"51","author":"E Dannaoui","year":"2003","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"ppat.1010858.ref016","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","article-title":"Posaconazole as Salvage Therapy for Zygomycosis","volume":"50","author":"RN Greenberg","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"ppat.1010858.ref017","doi-asserted-by":"crossref","first-page":"e0123021","DOI":"10.1128\/JCM.01230-21","article-title":"Epidemiology and Antifungal Susceptibilities of Mucoralean Fungi in Clinical Samples from the United States","volume":"59","author":"H Badali","year":"2021","journal-title":"J Clin Microbiol"},{"issue":"5","key":"ppat.1010858.ref018","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1128\/AAC.05956-11","article-title":"In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole","volume":"56","author":"V Salas","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ppat.1010858.ref019","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.mmcr.2016.03.002","article-title":"Isavuconazole as salvage therapy for mucormycosis","volume":"11","author":"B Graves","year":"2016","journal-title":"Medical Mycology Case Reports"},{"issue":"7","key":"ppat.1010858.ref020","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1473-3099(16)00127-4","article-title":"Isavuconazole: an azole active against mucormycosis","volume":"16","author":"E Roilides","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"ppat.1010858.ref021","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/myc.12909","article-title":"Antifungal combinations in Mucorales: A microbiological perspective","volume":"62","author":"P Schwarz","year":"2019","journal-title":"Mycoses"},{"issue":"3","key":"ppat.1010858.ref022","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis.","volume":"47","author":"C Reed","year":"2008","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"10","key":"ppat.1010858.ref023","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/jac\/dkab233","article-title":"Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis","volume":"76","author":"T Gebremariam","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"ppat.1010858.ref024","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12371","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013","volume":"20","author":"OA Cornely","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 1","key":"ppat.1010858.ref025","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1093\/cid\/cir885","article-title":"Combination therapy for mucormycosis: why, what, and how","volume":"54","author":"B Spellberg","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"5","key":"ppat.1010858.ref026","doi-asserted-by":"crossref","first-page":"O336","DOI":"10.1111\/1469-0691.12408","article-title":"Local control of rhino-orbito-cerebral mucormycosis dramatically impacts survival","volume":"20","author":"P Vironneau","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"ppat.1010858.ref027","doi-asserted-by":"crossref","first-page":"e1000549","DOI":"10.1371\/journal.pgen.1000549","article-title":"Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication","volume":"5","author":"LJ Ma","year":"2009","journal-title":"PLoS Genet"},{"issue":"9","key":"ppat.1010858.ref028","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00390-17","article-title":"Prophylactic Treatment with VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection","volume":"61","author":"T Gebremariam","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"ppat.1010858.ref029","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00178-20","article-title":"Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus","volume":"64","author":"T Gebremariam","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"ppat.1010858.ref030","doi-asserted-by":"crossref","first-page":"e0038022","DOI":"10.1128\/aac.00380-22","article-title":"The Combination Treatment of Fosmanogepix and Liposomal Amphotericin B Is Superior to Monotherapy in Treating Experimental Invasive Mold Infections","volume":"66","author":"T Gebremariam","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"15","key":"ppat.1010858.ref031","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.","volume":"81","author":"M Hoenigl","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"ppat.1010858.ref032","doi-asserted-by":"crossref","first-page":"e02949","DOI":"10.1128\/mBio.02949-19","article-title":"A Novel Resistance Pathway for Calcineurin Inhibitors in the Human-Pathogenic Mucorales Mucor circinelloides","volume":"11","author":"S Vellanki","year":"2020","journal-title":"MBio"},{"issue":"4","key":"ppat.1010858.ref033","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.chom.2019.08.004","article-title":"Calcium-Calmodulin-Calcineurin Signaling: A Globally Conserved Virulence Cascade in Eukaryotic Microbial Pathogens","volume":"26","author":"H-S Park","year":"2019","journal-title":"Cell Host Microbe"}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1010858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T21:42:32Z","timestamp":1701207752000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1010858"}},"subtitle":[],"editor":[{"given":"Anuradha","family":"Chowdhary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1010858","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,13]]}}}